MGC Pharmaceuticals (ASX:MXC) receives $4m purchase order
MGC Pharmaceuticals (MXC) receives an order for more than $4 million for…
Mgc Pharmaceuticals Ltd (MXC:ASX)
5.0¢
-0.001 (-1.96%)
MCAP $120.2M
Last trade
16.10pm 22/10/2021
20mins delayed
Latest Announcements
15/10/2021 Price SensitivePSMXCMgc Pharmaceuticals Ltd
2,204
MCap
12/10/2021MXCMgc Pharmaceuticals Ltd
1,242
MCap
07/10/2021MXCMgc Pharmaceuticals Ltd
07/10/2021MXCMgc Pharmaceuticals Ltd
167
MCap
07/10/2021MXCMgc Pharmaceuticals Ltd
164
MCap
07/10/2021MXCMgc Pharmaceuticals Ltd
07/10/2021MXCMgc Pharmaceuticals Ltd
07/10/2021 Price SensitivePSMXCMgc Pharmaceuticals Ltd
1,339
MCap
Company Overview
MGC Pharmaceuticals Limited is an Australia-based biopharma company. The Company is primarily focused on producing standardized, phytocannabinoid and plant-derived medicines. The Company’s Nature to Medicine strategy comprises the entire supply chain, from botanical research, to develop new strains of Cannabis Sativa, preclinical and clinical research, product manufacturing, distribution, as well as the development of drug delivery systems. The Group has also completed a Phase II double-blind, randomized, placebo controlled clinical trial in Israel and India, to evaluate the safety and efficacy of a natural anti-inflammatory based formulation ArtemiC on patients diagnosed with Corona Virus Disease 2019 (COVID-19).
